Among the 75 patients with available material for STAG2 amplicon sequencing, there was no difference in EFS (P = 0.18) or OS (P = 0.10) for patients with STAG2 mutated vs. STAG2 wild-type tumours (Supplemental Fig. 1A, B). This evidence concerns the gene STAG2 and neoplasm.